Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention
用于结肠癌化学预防的一氧化氮嵌合药物
基本信息
- 批准号:8037143
- 负责人:
- 金额:$ 30.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-05-01 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:Aberrant crypt fociAccountingAdverse effectsAdverse eventAnimal ModelAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsApoptosisApoptoticAspirinAttenuatedAzoxymethaneBiologicalBiological AssayBiological MarkersCancer cell lineCarcinogensCardiovascular systemCause of DeathCell Culture TechniquesCell LineChemopreventionChemopreventive AgentChimera organismClinicClinicalClinical TrialsColonColon CarcinomaColonic AdenomaColorectal CancerCombination Drug TherapyCombined Modality TherapyDNA DamageDataDatabasesDevelopmentDisulfidesDoseElementsEndoscopyEnzyme InductionEnzymesEventExplosionFunctional disorderGoalsHealthHumanIn VitroIncidenceIndividualIndomethacinInduction of ApoptosisInflammationInflammatory ResponseInterventionIsosorbide DinitrateKupffer CellsLeadLengthLesionLinkMalignant NeoplasmsMeasuresMetabolicModelingMolecularMutationNew AgentsNitratesNitric OxideNitric Oxide DonorsNon-Steroidal Anti-Inflammatory AgentsPTGS2 genePathologyPathway interactionsPharmaceutical ChemistryPharmaceutical PreparationsPhasePilot ProjectsPolypsPopulationPre-Clinical ModelPreventionPrincipal InvestigatorProliferation MarkerPropertyProstaglandinsProteinsRattusReducing AgentsReportingRiskRodentSafetyScreening procedureSignal PathwayStagingStem cellsStructureStructure-Activity RelationshipTestingTherapeuticTimeTime StudyTissuesadenomaarmbasecancer chemopreventioncancer riskcarcinogenesischimera drugdesigndrug candidategastrointestinalimprovedin vitro activityin vivoinhibitor/antagonistmanmetabolic abnormality assessmentmimeticsnovelpharmacophorepre-clinical researchprogramspublic health relevancesmall moleculesuccesstherapeutic targettumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant):
Colorectal cancer (CRC) is a leading cause of death in the US: chemoprevention of CRC represents an important therapeutic target and an unmet need. Anti-inflammatory agents (NSAIDs, COX-2s) have shown promise in preclinical research and clinical trials, but carry the burden of severe gastrointestinal (GI) or cardiovascular side effects. NO-donor NSAIDs, which are aliphatic nitrates, were designed to utilize the biological activity of nitric oxide (NO) to counteract the GI side effects of NSAIDs, which been borne out in the clinic. On the basis of data on NO-ASA and our preliminary data on GT 094, NO chimera (aliphatic nitrates containing one or more additional pharmacophores) we propose that NO chimeras are drug candidates for CRC chemoprevention and GT-094 represents a lead compound. It is the goal of this proposal to develop structure activity relationships (SAR) for NO chimera drugs, in particular containing NSAID containing pharmacophores, studying (i) anti- inflammatory (ii) anti-proliferative (iii) phase 2 (cytoprotective) enzyme inductiion and (iv) apoptotic activity activity, to correlate structurewith activity. The objective is to design and optimize a drug candidate or combination therapy for CRC chemoprevention. Aberrant crypt foci (ACF) are seen as an early precursor stage to colon adenomas and cancer in man; and in animal models a good correlation between ACF number and tumorigenesis has been reported. It is an objective of this proposal to measure ACF lesions and biomarkers of inflammation and proliferation that correlate with CRC tumorigenesis in animal models, and to correlate with such markers in cell culture. Success will result from our unique combination of expertise in NO-based medicinal chemistry and ACF pathophysiology. Specific aims: 1. To use the rat AOM model of CRC to assess in vivo the potency, efficacy and mechanism of the lead NO chimera, GT 094, and subsequently, to assess optimized NO chimera drug candidates and combination therapies. 2. To design and synthesize NO chimeras, component structural elements, and control compounds to optimize structure towards CRC chemoprevention. 3. To study these compounds in colon cell culture, to derive SAR correlations and to establish correlations with in vivo activity, to aid in design and optimazation of drug candidates. Completion of these aims will yield new drug candidates for CRC chemoprevention and improved understanding of chemopreventive pathways in CRC. PUBLIC HEALTH RELEVANCE: To develop structure activity relationships for NO chimera drugs, in particular NSAID containing disulfides, to understand the contributions to anti-inflammatory and anti-proliferative activity, and thus to design optimized drug candidates for CRC chemoprevention. Aberrant crypt foci (ACF) are seen as an early precursor stage to colon adenomas and cancer in man; and in animal models a good correlation between ACF number and tumorigenesis has been reported.
描述(由申请人提供):
在美国,结直肠癌(CRC)是主要的死亡原因:结直肠癌的化学预防是一个重要的治疗目标,也是一个未得到满足的需求。抗炎药(NSAIDs,COX-2s)在临床前研究和临床试验中显示出良好的前景,但会带来严重的胃肠道(GI)或心血管副作用。NO供体非甾体抗炎药(NSAIDs)是一种脂肪族硝酸盐,是利用一氧化氮(NO)的生物活性来对抗NSAIDs的胃肠道副作用而设计的,已经在临床上得到了证实。根据NO-ASA的数据和我们关于GT 094的初步数据,没有嵌合体(含有一个或多个额外药效团的脂肪族硝酸盐),我们认为没有嵌合体是结直肠癌化学预防的候选药物,GT-094代表先导化合物。这项建议的目标是建立非嵌合体药物,特别是含有非甾体抗炎药的药效团的构效关系(SAR),研究(I)抗炎(Ii)抗增殖(Iii)阶段2(细胞保护)酶诱导和(Iv)凋亡活性,以使结构与活性相关联。其目的是设计和优化用于结直肠癌化学预防的候选药物或联合疗法。异常隐窝病灶(ACF)被认为是人类结肠腺瘤和癌症的早期先兆;在动物模型中,ACF数量与肿瘤发生有很好的相关性。这项建议的目的是在动物模型中测量与结直肠癌发生相关的ACF损伤和炎症和增殖的生物标记物,并在细胞培养中与这些标记物相关联。成功将源于我们在NO药物化学和ACF病理生理学方面的独特专业知识组合。具体目的:1.利用大鼠结直肠癌AOM模型,在体内评价非嵌合体先导剂GT 094的药效、疗效和作用机制,进而评价优化的非嵌合体候选药物和联合治疗方案。2.设计和合成非嵌合体、组成结构元件和控制化合物,以优化结构,从而达到预防结直肠癌的目的。3.研究这些化合物在结肠细胞培养中的作用,推导SAR相关性,并建立与体内活性的相关性,以帮助设计和优化候选药物。完成这些目标将产生用于结直肠癌化学预防的新候选药物,并提高对结直肠癌化学预防途径的了解。公共卫生相关性:开发非嵌合体药物,特别是含有二硫化物的非甾体抗炎药的构效关系,了解其对抗炎和抗增殖活性的贡献,从而设计用于结直肠癌化学预防的优化候选药物。异常隐窝病灶(ACF)被认为是人类结肠腺瘤和癌症的早期先兆;在动物模型中,ACF数量与肿瘤发生有很好的相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory R. J Thatcher其他文献
Gregory R. J Thatcher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory R. J Thatcher', 18)}}的其他基金
Nonlipogenic ABCA1 inducers for ADRD - Supplement
ADRD 的非脂肪生成 ABCA1 诱导剂 - 补充品
- 批准号:
10832305 - 财政年份:2022
- 资助金额:
$ 30.8万 - 项目类别:
Partial Agonists at Estrogen Receptor alpha for Breast Cancer Therapy
用于乳腺癌治疗的雌激素受体α部分激动剂
- 批准号:
9251781 - 财政年份:2015
- 资助金额:
$ 30.8万 - 项目类别:
Nomethiazoles Harnessing GABA and NO mimetic activity for Alzheimer's therapy
诺美噻唑利用 GABA 和 NO 模拟活性治疗阿尔茨海默病
- 批准号:
8590612 - 财政年份:2013
- 资助金额:
$ 30.8万 - 项目类别:
Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention
用于结肠癌化学预防的一氧化氮嵌合药物
- 批准号:
7774413 - 财政年份:2008
- 资助金额:
$ 30.8万 - 项目类别:
Harnessing GABA and NO mimetic activity for Alzheimer's therapy
利用 GABA 和 NO 模拟活性治疗阿尔茨海默病
- 批准号:
7880128 - 财政年份:2008
- 资助金额:
$ 30.8万 - 项目类别:
Harnessing GABA and NO mimetic activity for Alzheimer's therapy
利用 GABA 和 NO 模拟活性治疗阿尔茨海默病
- 批准号:
7534219 - 财政年份:2008
- 资助金额:
$ 30.8万 - 项目类别:
Nitric Oxide Chimera Drugs for Colon Cancer Chemoprevention
用于结肠癌化学预防的一氧化氮嵌合药物
- 批准号:
8233559 - 财政年份:2008
- 资助金额:
$ 30.8万 - 项目类别:
Harnessing GABA and NO mimetic activity for Alzheimer's therapy
利用 GABA 和 NO 模拟活性治疗阿尔茨海默病
- 批准号:
8111768 - 财政年份:2008
- 资助金额:
$ 30.8万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 30.8万 - 项目类别: